Graham Worrall1. 1. Memorial University of Newfoundland, Newfoundland, Canada.
Abstract
INTRODUCTION: Herpes simplex virus type 1 infection usually causes a mild, self-limiting painful blistering around the mouth, with 20% to 40% of adults affected at some time. Primary infection usually occurs in childhood, after which the virus is thought to remain latent in the trigeminal ganglion. Recurrence may be triggered by factors such as exposure to bright light, stress, and fatigue. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antiviral treatments for the first attack of herpes labialis? What are the effects of interventions aimed at preventing recurrent attacks of herpes labialis? What are the effects of treatments for recurrent attacks of herpes labialis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 27 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: oral antiviral agents, sunscreen, topical anaesthetic agents, topical antiviral agents, and zinc oxide cream.
INTRODUCTION:Herpes simplex virus type 1 infection usually causes a mild, self-limiting painful blistering around the mouth, with 20% to 40% of adults affected at some time. Primary infection usually occurs in childhood, after which the virus is thought to remain latent in the trigeminal ganglion. Recurrence may be triggered by factors such as exposure to bright light, stress, and fatigue. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of antiviral treatments for the first attack of herpes labialis? What are the effects of interventions aimed at preventing recurrent attacks of herpes labialis? What are the effects of treatments for recurrent attacks of herpes labialis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to February 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 27 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: oral antiviral agents, sunscreen, topical anaesthetic agents, topical antiviral agents, and zinc oxide cream.
Authors: L H Kaminester; R J Pariser; D M Pariser; J S Weiss; J S Shavin; L Landsman; H G Haines; D W Osborne Journal: J Am Acad Dermatol Date: 1999-12 Impact factor: 11.527
Authors: Spotswood L Spruance; Neil Bodsworth; Harvey Resnick; Marcus Conant; Claude Oeuvray; Joseph Gao; Kamal Hamed Journal: J Am Acad Dermatol Date: 2006-07 Impact factor: 11.527
Authors: T G Evans; D I Bernstein; G W Raborn; J Harmenberg; J Kowalski; S L Spruance Journal: Antimicrob Agents Chemother Date: 2002-06 Impact factor: 5.191
Authors: Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley Journal: J Clin Virol Date: 2011-09-01 Impact factor: 3.168
Authors: Alex Semprini; Joseph Singer; Irene Braithwaite; Nick Shortt; Darmiga Thayabaran; Melanie McConnell; Mark Weatherall; Richard Beasley Journal: BMJ Open Date: 2019-05-14 Impact factor: 2.692